文献速递关节外科

全膝关节置换术后追加24小时口服氨甲环酸对比单次术前静脉给药的随机对照试验(TRAC-24)

Oral tranexamic acid for an additional 24 hours postoperatively versus a single preoperative intravenous dose for reducing blood loss in total knee arthroplasty: results of a randomized controlled trial (TRAC-24).
PubMed 文献 · Bone Joint J · 2021-01-01

TRAC-24为前瞻性单中心随机对照试验,纳入552例全膝关节置换患者(含高危患者),比较围术期1g静脉氨甲环酸加术后24小时四次口服1g、单次静脉给药及不用药三组。结果显示联合口服组48小时间接计算失血量733.5ml,显著低于单次静脉组的859.2ml(均差-125.8ml,95%CI -194.0至-57.5,p<0.001),各组死亡率及血栓栓塞事件无差异。

要点

  • 全膝关节置换围术期1g静脉氨甲环酸加术后24小时四次口服1g可进一步减少失血。
  • 联合方案48小时失血量733.5ml,较单次静脉给药859.2ml显著降低。
  • 高危患者使用氨甲环酸未见死亡率或血栓栓塞事件差异。

核心结论

  • 全膝关节置换围术期静脉1g氨甲环酸加术后24小时四次口服1g,较单次围术期静脉1g显著减少失血。
  • 氨甲环酸在有血栓栓塞、心血管或脑血管疾病史的患者中 appears safe。

研究设计与样本

  • TRAC-24为前瞻性、IV期、单中心、开放标签、平行组随机对照试验,纳入全膝关节置换患者包括高危患者。
  • 552例患者随机分为三组:联合口服组241例、单次静脉组243例、不用药组68例,551例纳入最终分析。
  • 主要结局为48小时间接计算失血量(IBL)。

主要发现

  • 联合口服组48小时IBL为733.5ml(SD 384.0),单次静脉组为859.2ml(SD 363.6ml),均差-125.8ml(95%CI -194.0至-57.5;p<0.001)。
  • 各组死亡率或血栓栓塞事件无差异。

关键数值与推荐

  • 联合口服组方案:手术时静脉1g氨甲环酸,术后24小时口服四次1g。
  • 单次静脉组仅术中静脉1g氨甲环酸;不用药组未接受氨甲环酸。

临床怎么用

  • 全膝关节置换可考虑围术期静脉1g氨甲环酸联合术后24小时四次口服1g以进一步减少失血。
  • 有血栓栓塞、心血管或脑血管疾病史的高危患者使用该方案未见死亡率或血栓栓塞事件差异。

局限性

  • 单中心、开放标签设计。
  • 不用药组样本量较小(68例)。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

AIMS: In total knee arthroplasty (TKA), blood loss continues internally after surgery is complete. Typically, the total loss over 48 postoperative hours can be around 1,300 ml, with most occurring within the first 24 hours. We hypothesize that the full potential of tranexamic acid (TXA) to decrease TKA blood loss has not yet been harnessed because it is rarely used beyond the intraoperative period, and is usually withheld from 'high-risk' patients with a history of thromboembolic, cardiovascular, or cerebrovascular disease, a patient group who would benefit greatly from a reduced blood loss. METHODS: TRAC-24 was a prospective, phase IV, single-centre, open label, parallel group, randomized controlled trial on patients undergoing TKA, including those labelled as high-risk. The primary outcome was indirect calculated blood loss (IBL) at 48 hours. Group 1 received 1 g intravenous (IV) TXA at the time of surgery and an additional 24-hour postoperative oral regime of four 1 g doses, while Group 2 only received the intraoperative dose and Group 3 did not receive any TXA. RESULTS: Between July 2016 and July 2018, 552 patients were randomized to either Group 1 (n = 241), Group 2 (n = 243), or Group 3 (n = 68), and 551 were included in the final analysis. The blood loss did differ significantly between the two intervention groups (733.5 ml (SD 384.0) for Group 1 and 859.2 ml (SD 363.6 ml) for Group 2; mean difference -125.8 ml (95% confidence interval -194.0 to -57.5; p < 0.001). No differences in mortality or thromboembolic events were observed in any group. CONCLUSION: These data support the hypothesis that in TKA, a TXA regime consisting of IV 1 g perioperatively and four oral 1 g doses over 24 hours postoperatively significantly reduces blood loss beyond that achieved with a single IV 1 g perioperative dose alone. TXA appears safe in patients with history of thromboembolic, cardiovascular, and cerebrovascular disease. Cite this article: Bone Joint J 2021;103-B(10):1595-1603.

来源:Bone Joint J,查看原文。版权归原作者所有。

引用

  1. Magill P, Hill JC, Bryce L, et al. Oral tranexamic acid for an additional 24 hours postoperatively versus a single preoperative intravenous dose for reducing blood loss in total knee arthroplasty: results of a randomized controlled trial (TRAC-24). Bone Joint J. 2021. PMID: 34587808. doi:10.1302/0301-620X.103B10.BJJ-2020-2308.R1

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。